▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #255 by analyst upside · 2026-11-13
APRE
Aprea Therapeutics, Inc.
Healthcare · Market Cap $6M · P/E 0x
ANALYST PRICE TARGET
+650.0%
implied upside to consensus target
Current Price $0.44
Consensus Target $3.3
Bull Target $5.0
Bear Target $1.2
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
3
Hold
0
Sell
0
52-Week Low $0.41
52-Week High $1.49
YTD Return -48.4%
FUNDAMENTALS
Market Cap $6M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.58
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.41
52-Week High $1.49
Current Price $0.44
Bear Target $1.2
Bull Target $5.0
● Now $0.44 ● Target $3.3
TRADING DATA
Avg Volume 314K
YTD Return -48.4%
Analyst Count 4
Consensus Buy
Upside to Target +650.0%
Last Updated 2026-11-13

ANALYST SUMMARY

Aprea Therapeutics, Inc. (APRE) is currently trading at $0.44 with a Wall Street consensus price target of $3.3, implying potential upside of 650.0% over the next 12 months. 4 analysts currently cover APRE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $5.0, while the most cautious has a target of $1.2.

APRE operates in the Healthcare sector with a market capitalisation of $6M. The stock is down 48.4% year-to-date and is currently trading near the lower end of its 52-week range of $0.41 – $1.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for APRE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Ladenburg Thalmann ● Initiated
Buy 2026-10-14 25% win rate (8 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-08-13 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-05-14 Building track record
Oppenheimer ● Initiated
Outperform 2026-05-07 14% win rate (7 calls)
Wedbush reit
Outperform → Outperform 2026-03-31 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-31 31% win rate (48 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-02-10 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-01-29 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →